Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLP-1002 in Osteoarthritis Pain
NCT04677933Phase 1Completed
- Sponsor
- OliPass Corporation
- Start
- Jun 2020
- Primary completion
- Dec 2020
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OLP-1002 in osteoarthritis (OA) (3 arms), sponsored by OliPass Corporation. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at Day 45, Vital Sign- heart rate at Day 45 and 5 more. Started Jun 2020; status: completed.
02
Drugs
OLP-1002
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04677933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677933.